Patents Examined by Kevin E. Weddington
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 11236104
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: February 1, 2022
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
    Patent number: 11234972
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: February 1, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Elfrida Benjamin
  • Methods of inducing weight loss
    Patent number: 11219236
    Abstract: The present disclosure relates to a method of inducing weight loss and/or preventing weight gain in a subject affected by administering certain diets selected based on the fasting blood glucose and/or the fasting insulin of the subject. The present disclosure further provides personalized dietary instruction, based on the fasting blood glucose and/or the fasting insulin of a subject, with the potential to improve the weight loss and prevent weight regain. The present disclosure further relates to methods for predicting weight loss success and classifying responsiveness of a subject to a certain diet as well as methods for selecting a weight loss or a weight gain diet for a subject based on the fasting blood glucose and/or the fasting insulin of the subject.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 11, 2022
    Assignees: Gelesis LLC, University of Copenhagen
    Inventors: Arne Astrup, Christian Ritz, Mads Fiil Hjorth, Yishai Zohar
  • Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agent
    Patent number: 11213533
    Abstract: This invention relates to combination products comprising an amidine selected from dibromopropamidine and diminazene or a pharmaceutically acceptable salt or solvate thereof; and a tetracycline anti-bacterial agent. The combination products are suitable for use in the treatment of bacterial infections or diseases.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: January 4, 2022
    Assignee: UNION Therapeutics A/S
    Inventors: Morten Otto Alexander Sommer, Rasmus Toft-Kehler
  • Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions
    Patent number: 11207347
    Abstract: Stabilized amorphous calcium carbonate (ACC) for treatment of several neurological, muscular and infertility diseases and conditions is provided. In particular, the stabilized ACC may be used in the treatment of axonal defects and muscular dystrophy. In addition, provided are improved methods used in assistant reproductive technology. Examples of such methods are in vitro fertilization and improvement of sperm quality. The improved IVF method, for example, comprises addition of the stabilized ACC to the cell culture medium in which the stages of fertilization and embryo development occurs.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: December 28, 2021
    Assignee: AMORPHICAL LTD.
    Inventors: Yosef Ben, Abraham Shahar, Amir Arav
  • Photoprotective compositions containing malassezia-derived compounds and/or chemical analogs thereof
    Patent number: 11202748
    Abstract: The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and/or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: December 21, 2021
    Assignee: Versicolor Technologies, LLC
    Inventors: Michael Einziger, Ann Marie Simpson
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 11185550
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: November 30, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Subcutaneous administration of a P2Yreceptor antagonist
    Patent number: 11179390
    Abstract: The present invention relates to a P2Y12 receptor antagonist selected from the group consisting of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4 carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, and (1S,2R,3S,4R)-4-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2,3-triol, or a pharmaceutically acceptable salt thereof, for use as a medicament by subcutaneous or intradermal administration.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: November 23, 2021
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Martine Baumann, Markus Kramberg, Markus Rey, Markus Riederer, Sebastien Roux
  • Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
    Patent number: 11180518
    Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 23, 2021
    Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
    Inventors: Dorothea Becker, Thomas M. Jovin, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Armin Giese, Tiago F. Outeiro, Diana F. Lazaro, Michael P. Schön, Margarete Schön
  • Dosage regimen for picotamide for the use in migraine
    Patent number: 11166946
    Abstract: Picotamide (4-methoxy-N,N?-bis(pyridin-3-ylmethyl)benzene-1,3-dicarboxamide, CAS-no. 32828-81-2) can be used in the treatment and/or prevention of migraine with aura. A specific dosage regimen is used in this treatment and/or prevention, where, in a first period, picotamide is administered for 2 to 6 months, and the first period is followed by a second period of 1 to 3 months without picotamide administration.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: November 9, 2021
    Assignee: CURATIS AG
    Inventor: Arnim Pause
  • Thermoreversible compositions for administration of therapeutic agents
    Patent number: 11160868
    Abstract: The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: November 2, 2021
    Assignee: Frequency Therapeutics, Inc.
    Inventors: Christopher Loose, Will McLean, Megan Harrison, Michael R. Jirousek
  • Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
    Patent number: 11160796
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 2, 2021
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Arturo Molina
  • Pharmaceutical composition for treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph
    Patent number: 11154530
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver cancer and a method for producing same, the composition comprising tetraarsenic hexoxide in which the content of tetraarsenic hexoxide crystalline polymorph a (As4O6-a) is 99% or more. The composition of the present invention exhibits an excellent cancer cell proliferation inhibition effect and thus can be useful as an anticancer drug.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 26, 2021
    Assignee: CHEMAS CO., LTD.
    Inventors: Ill Ju Bae, Zenglin Lian
  • Solid solution compositions and use in chronic inflammation
    Patent number: 11154500
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: May 25, 2020
    Date of Patent: October 26, 2021
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Methods of treating mixed dyslipidemia
    Patent number: 11154526
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: October 26, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain
    Patent number: 11147799
    Abstract: This disclosure relates to a pharmaceutical composition for topical use wherein the active pharmaceutical ingredient consists of the co-analgesic phenytoin and at least one further co-analgesic, and a method for producing the pharmaceutical composition. In addition, the disclosure relates to the pharmaceutical composition for use in the treatment of chronic pain.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: October 19, 2021
    Assignees: TOPICAL INNOVATIONS B.V.
    Inventors: David Jos Kopsky, Jan Marius Keppel Hesselink
  • Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
    Patent number: 11141411
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: October 12, 2021
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
    Patent number: 11141413
    Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 12, 2021
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
  • Methods of treating overweight and obesity
    Patent number: 11139056
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: October 5, 2021
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Preston Klassen, Kristin Taylor
  • Solid dispersion forms of rifaximin
    Patent number: 11129817
    Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 28, 2021
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: Pam Golden, Mohammed A. Kabir